BRAINSTORM CELL THERAPEUTICS INC. By Chris Wack
BrainStorm Cell Therapeutics shares were halted at 43 cents in premarket trading in preparation for a meeting of the U.S. Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee on Wednesday.
The FDA meeting, scheduled to take place from 10 a.m. to 6 p.m. ET, will review BrainStorm's Biologics License Application for NurOwn for the treatment of amyotrophic lateral sclerosis.
BrainStorm's BLA for NurOwn has a Prescription Drug User Fee Act action date targeted to occur by Dec. 8, 2023.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
09-27-23 0729ET
